This content is machine translated Follow-up of the NeoSphere study Compelling data on the neoadjuvant use of pertuzumab NeoSphere is a phase II trial in which 417 women with newly diagnosed HER2-positive, operable, locally advanced or inflammatory early breast cancer were randomized to four different neoadjuvant therapy arms.…
